1.CONCLUSIONS Weight reduction with GLP-1 receptor agonists was associated with a shift toward a more favorable cardiovascular risk profile.
结论：GLP-1受体激动剂治疗后的体重减轻与心血管危险因素谱向更有益的方向转变有关。
2.Dr Munger, though, found that both GLP-1 and the receptor molecule that picks it up and thus allows it to act are found in taste buds too.
而芒杰博士发现，在味蕾中也有GLP-1和接收GLP-1并使其发生作用的受体的存在。
3.Deteriorations in glucose homeostasis can develop in the absence of any impairment in GIP or GLP-1 levels.
在GIP和GLP-1水平没有受损的情况下，葡萄糖稳态仍不断被破坏。
4.This increase in GLP-1 secretion may be mediated via stimulation of sweet-taste receptors on L-cells by artificial sweetener.
GLP-1分泌增加是通过人工甜味剂刺激L细胞上的甜味受体调节的。
5.This phenomenon is called the incretin effect and is caused by the two incretin hormones GIP and GLP-1.
这种现象被称为肠效应和所造成的两个肠肽激素和GLP-1。
6.Dipeptidyl peptidase (DPP-IV) inhibitors suppress the degradation of many peptides, including GLP-1, thereby extending their bioactivity.
二肽酶（民进党四）抑制剂抑制多肽降解，包括血糖素样肽1，从而延长它们的生物活性。
7.Conclusions: Orlistat alters gastric and gallbladder emptying and reduces the postprandial secretion of GLP-1, PYY and CCK.
结论：奥利斯特改变了胃和胆囊排空，并减少GLP-1，PYY和CCK的餐后分泌。
8.Consequently, the intracerebral glucose concentration remained constant in all regions, with and without GLP-1.
因此，用或不用GLP-1脑内所有区域葡萄糖浓度均保持恒定。
9.Conclusion GLP-1 analog can paly an important role in treatment of experimental diabetes mellitus through multiple ways.
结论：GLP-1类似物可以通过多种途径在治疗实验性糖尿病中发挥作用。
10.however, the cardiovascular effects of distinct GLP-1 peptides have received limited attention.
然而不同的胰高血糖素样肽1对心血管的效应却很少被关注。